Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous ste...

por Derman, Benjamin A., Stefka, Andrew T., Jiang, Ken, McIver, Amanda, Kubicki, Tadeusz, Jasielec, Jagoda K., Jakubowiak, Andrzej J.
Publicado 2021

Distinctive Patterns of MicroRNA Expression Associated with Karyotype in Acute Myeloid Leukaemia

por Dixon-McIver, Amanda, East, Phil, Mein, Charles A., Cazier, Jean-Baptiste, Molloy, Gael, Chaplin, Tracy, Andrew Lister, T., Young, Bryan D., Debernardi, Silvana
Publicado 2008

ATR-16 syndrome: mechanisms linking monosomy to phenotype

por Babbs, Christian, Brown, Jill, Horsley, Sharon W, Slater, Joanne, Maifoshie, Evie, Kumar, Shiwangini, Ooijevaar, Paul, Kriek, Marjolein, Dixon-McIver, Amanda, Harteveld, Cornelis L, Traeger-Synodinos, Jan, Wilkie, Andrew O M, Higgs, Douglas R, Buckle, Veronica J
Publicado 2020

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

por Jakubowiak, Andrzej J., Jasielec, Jagoda K., Rosenbaum, Cara A., Cole, Craig E., Chari, Ajai, Mikhael, Joseph, Nam, Jennifer, McIver, Amanda, Severson, Erica, Stephens, Leonor A., Tinari, Kathryn, Rosebeck, Shaun, Zimmerman, Todd M., Hycner, Tyler, Turowski, Agata, Karrison, Theodore, Zonder, Jeffrey A.
Publicado 2019